Comparison of Efficacy and Safety Between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia

Overview

Journal Schizophr Res Treatment

Publisher Wiley

Date 2021 Dec 6

PMID 34868682

Citations 3

Authors

Thanompong Sathienluckana

Pornyupa Tiangpattanawong

Karnpreena Chaiyasukthananoan

Pannapat Jittayanan

Hathaipat Sawetwangsing

Punyawee Puchsaka

Affiliations

Soon will be listed here.

Abstract

Background: Long-acting injectable (LAI) antipsychotics are used as a monotherapy in patients with schizophrenia. However, the combination of LAI and oral antipsychotics is commonly used in clinical practice, despite there being very limited studies investigating the efficacy and safety of this combination compared with LAI antipsychotic monotherapy.

Objective: To study the efficacy and safety of LAI antipsychotic monotherapy compared with the combination of LAI and oral antipsychotics in patients with schizophrenia.

Methods: This study was a retrospective cohort study, which classified eligible patients into two groups: the LAI antipsychotic monotherapy group and the combination of LAI and oral antipsychotic group. The primary outcome was hospitalization between groups. The duration of the study was 2 years.

Results: In total, 86 patients completed the study and were analysed (LAI antipsychotic monotherapy group: = 25; combination of LAI and oral antipsychotic group: = 61). There was no significant difference in hospitalization between the two groups ( = 1.000). For other outcomes, there were also no significant differences in both all-cause discontinuation ( = 0.667) and adverse drug reactions ( = 0.732) between the two groups.

Conclusion: The efficacy and safety of LAI antipsychotic monotherapy appeared similar to the combination of LAI and oral antipsychotics in patients with schizophrenia. Therefore, the combination of LAI and oral antipsychotics, which is commonly used in clinical practice, may not be necessary.

Citing Articles

Outcomes of long-acting injectable antipsychotics use in pregnancy: A literature review.

Pejcic A, Stefanovic S, Milosavljevic M, Janjic V, Folic M, Folic N World J Psychiatry. 2024; 14(4):582-599.

PMID: 38659600 PMC: 11036459. DOI: 10.5498/wjp.v14.i4.582.

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia.

Kamei H Medicina (Kaunas). 2022; 58(11).

PMID: 36363541 PMC: 9692600. DOI: 10.3390/medicina58111584.

Attitude and influencing factors of patients with schizophrenia toward long-acting injections: A community-based cross-sectional investigation in China.

Sun Y, Tong J, Feng Y, Fang H, Jiang T, Zhao L Front Public Health. 2022; 10:951544.

PMID: 36299738 PMC: 9589343. DOI: 10.3389/fpubh.2022.951544.

References

Yang K, Liao Y, Yang Y, Lin S, Liang C, Bai Y . Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN). CNS Drugs. 2021; 35(8):893-905. DOI: 10.1007/s40263-021-00838-5. View

Jin Y, Pollock B, Coley K, Miller D, Marder S, Florian J . Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol. 2009; 50(1):73-80. PMC: 3648660. DOI: 10.1177/0091270009343694. View

Rothe P, Heres S, Leucht S . Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method. Schizophr Res. 2017; 193:23-28. DOI: 10.1016/j.schres.2017.07.033. View

Aggarwal N, Sernyak M, Rosenheck R . Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications. J Clin Psychopharmacol. 2012; 32(3):323-8. DOI: 10.1097/JCP.0b013e31825244f6. View

Malla A, Chue P, Jordan G, Stip E, Koczerginski D, Milliken H . An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. Clin Schizophr Relat Psychoses. 2013; 9(4):198-208. DOI: 10.3371/CSRP.MACH.061213. View

Kane J, Aguglia E, Altamura A, Ayuso Gutierrez J, Brunello N, Fleischhacker W . Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol. 1998; 8(1):55-66. DOI: 10.1016/s0924-977x(97)00045-x. View

Kishimoto T, Nitta M, Borenstein M, Kane J, Correll C . Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013; 74(10):957-65. DOI: 10.4088/JCP.13r08440. View

Peuskens J, Demily C, Thibaut F . Treatment of cognitive dysfunction in schizophrenia. Clin Ther. 2005; 27 Suppl A:S25-37. DOI: 10.1016/j.clinthera.2005.07.015. View

Correll C, Citrome L, Haddad P, Lauriello J, Olfson M, Calloway S . The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. J Clin Psychiatry. 2016; 77(suppl 3):1-24. DOI: 10.4088/JCP.15032su1. View

10.

Higashi K, Medic G, Littlewood K, Diez T, Granstrom O, De Hert M . Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013; 3(4):200-18. PMC: 3805432. DOI: 10.1177/2045125312474019. View

11.

Lacro J, Dunn L, Dolder C, Leckband S, Jeste D . Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002; 63(10):892-909. DOI: 10.4088/jcp.v63n1007. View

12.

Yu H, Hsiao C, Chen K, Lee L, Chang W, Chi M . A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia--A nationwide study. Schizophr Res. 2015; 169(1-3):400-405. DOI: 10.1016/j.schres.2015.09.006. View

13.

Brissos S, Ruiz Veguilla M, Taylor D, Balanza-Martinez V . The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014; 4(5):198-219. PMC: 4212490. DOI: 10.1177/2045125314540297. View

14.

Kane J, Zhao C, Johnson B, Baker R, Eramo A, McQuade R . Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ. 2014; 18(2):145-54. PMC: 4743596. DOI: 10.3111/13696998.2014.979936. View

15.

Tiihonen J, Taipale H, Mehtala J, Vattulainen P, Correll C, Tanskanen A . Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA Psychiatry. 2019; 76(5):499-507. PMC: 6495354. DOI: 10.1001/jamapsychiatry.2018.4320. View

16.

Haddad P, Brain C, Scott J . Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014; 5:43-62. PMC: 4085309. DOI: 10.2147/PROM.S42735. View

17.

Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M . Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Can J Psychiatry. 2017; 62(9):604-616. PMC: 5593252. DOI: 10.1177/0706743717720448. View

18.

DESAI H, Seabolt J, Jann M . Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001; 15(6):469-94. DOI: 10.2165/00023210-200115060-00005. View

19.

Llorca P, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L . Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013; 13:340. PMC: 3898013. DOI: 10.1186/1471-244X-13-340. View

20.

Altamura A, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E . Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs. 2003; 63(5):493-512. DOI: 10.2165/00003495-200363050-00004. View